Research programme: anti-fungal therapeutics - Shionogi/Nissan Chemical
Latest Information Update: 03 Feb 2016
At a glance
- Originator Nissan Chemical Industries; Shionogi
- Class Antifungals; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mycoses